European Equities Traded in US as American Depositary Receipts Tread Water Friday, Up 3% for Week

MT Newswires Live2024-12-28

European equities traded in the US as American depositary receipts were edging 0.03% lower late Friday morning to 1,298.5 on the S&P Europe Select ADR Index, which is up nearly 3% for the week.

From continental Europe, the gainers were led by biotech firm Evaxion Biotech (EVAX) and biopharmaceutical company DBV Technologies (DBVT), which climbed 14.7% and 5.4% respectively. They were followed by medical device maker EDAP TMS (EDAP) and biopharmaceutical company Cellectis (CLLS), which increased 4.3% and 4% respectively.

The decliners from continental Europe were led by furniture maker Natuzzi (NTZ) and biopharmaceutical company Grifols (GRFS), which shed nearly 15% and 5% respectively. They were followed by internet browser company Opera (OPRA) and 3D printer company Materialise (MTLS), which dropped 2.6% and 2.7% respectively.

From the UK and Ireland, the gainers were led by biopharmaceutical companies NuCana (NCNA) and TC Biopharm (TCBP), which rose 6% and 1.7% respectively. They were followed by medical device maker Smith & Nephew (SNN) and oil and gas company Shell (SHEL), which were up 1.4% and 1.1% respectively.

The decliners from the UK and Ireland were led by biopharmaceutical company Biodexa Pharmaceuticals (BDRX) and biotech firm Autolus Therapeutics (AUTL), which fell 7% and 4.1% respectively. They were followed by biopharmaceutical company Mereo BioPharma Group (MREO) and biotech firm Trinity Biotech (TRIB), which were each down 2.6%.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment